Barcelona – September 30, 2026 -- Servier is standardizing customer reference data across more than 80 countries using Veeva OpenData, part of a global push to build an AI-ready data foundation for its commercial and medical teams.
Cambridge, Mass. – September 30, 2026 -- Insilico Medicine (HKEX: 3696) has nominated ISM1354, an AI-designed small molecule GIPR antagonist, as a preclinical candidate for obesity, type 2 diabetes and potential cardiovascular applications tied to obesity-associated heart failure.
South San Francisco, Calif. – September 12, 2026 -- IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase 3 trial testing darovasertib combined with crizotinib as adjuvant therapy for primary uveal melanoma, targeting a disease segment with no approved systemic treatment options.
